Piper Sandler analyst maintains an Overweight rating on Teva, citing positive feedback on duvakitug's potential in treating IBD.

Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...

"Sanofi and Teva’s duvakitug meets primary endpoints in Phase IIb trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has ...

Teva Pharmaceutical's Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. See why I ...

The safety and efficacy of duvakitug have not been reviewed by any regulatory authority. Sanofi and Teva are collaborating to co-develop and co-commercialize duvakitug for the treatment of UC and CD.

Teva Pharmaceutical Industries Ltd. (NYSE ... including the positive Phase 2b results for our duvakitug (anti-Tl1A) asset. These results pave the way for pivotal trials in Crohn's disease and ...

Teva's shares surged 18% to $19.53 in premarket trading. Sanofi's American depositary receipts were up 3.7% at $47.57. Duvakitug was generally well tolerated across both patient groups and showed ...

Teva and Sanofi are co-developing the IBD treatment Teva and Sanofi are co-developing Teva’s duvakitug for the treatment of UC and CD. Each company will equally share the development costs as ...

The firm discussed the development of anti-TL1A antagonist duvakitug beyond just inflammatory ... for the shares is justified amid Teva’s growing brand neuropsychiatry sales footprint and ...

Reports Q4 revenue $4.2B, consensus $4.12B. Richard Francis, Teva‘s (TEVA) President and CEO, said: “2024 marked a transformative year for ...